Publications by authors named "J Greg Slatter"

Claim this Profile
I
Identification and Characterization of ACP-5862, the Major Circulating Active Metabolite of Acalabrutinib: Both Are Potent and Selective Covalent Bruton Tyrosine Kinase Inhibitors .
Terry Podoll, Paul G Pearson, Allard Kaptein, Jerry Evarts, Gerjan de Bruin, J Greg Slatter

J Pharmacol Exp Ther· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment.
Yan Xu, Raquel Izumi, Helen Nguyen, Anna Kwan, Howard Kuo, J Greg Slatter

J Clin Pharmacol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A population pharmacokinetic-pharmacodynamic model of navtemadlin, its glucuronide metabolite (M1) and serum macrophage inhibitory cykokine-1 (MIC-1).
Lu Zhang, Bill Poland, Michelle Green, Shekman Wong, J Greg Slatter

Xenobiotica· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Macrophage Inhibitory Cytokine-1 Pharmacodynamics of the Murine Double Minute 2 Inhibitor, Navtemadlin (KRT-232) in Fed and Fasted Healthy Subjects.
Shekman Wong, Cecile Krejsa, Dana Lee, Anna Harris, Emilie Simard, J Greg Slatter

Clin Pharmacol Drug Dev· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices.
Xavier J H Pepin, Andrea J Moir, James C Mann, Natalie J Sanderson, Richard Barker, J Greg Slatter

Eur J Pharm Biopharm· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis